From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).
Radiol Cardiothorac Imaging. 2024 Apr;6(2):e230098. doi: 10.1148/ryct.230098.
Purpose To develop an approach for in vivo detection of interstitial cardiac fibrosis using PET with a peptide tracer targeting proteolyzed collagen IV (T-peptide). Materials and Methods T-peptide was conjugated to the copper chelator MeCOSar (chemical name, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid) and radiolabeled with copper 64 (Cu). PET/CT scans were acquired following intravenous delivery of Cu-T-peptide-MeCOSar (0.25 mg/kg; 18 MBq ± 2.7 [SD]) to male transgenic mice overexpressing β2-adrenergic receptors with intermediate (7 months of age; = 4 per group) to severe (10 months of age; = 11 per group) cardiac fibrosis and their wild-type controls. PET scans were also performed following coadministration of the radiolabeled probe with nonlabeled T-peptide in excess to confirm binding specificity. PET data were analyzed by tests for static scans and analysis of variance tests (one- or two-way) for dynamic scans. Results PET/CT scans revealed significantly elevated (2.24-4.26-fold; < .05) Cu-T-peptide-MeCOSar binding in the fibrotic hearts of aged transgenic β2-adrenergic receptor mice across the entire 45-minute acquisition period compared with healthy controls. The cardiac tracer accumulation and presence of diffuse cardiac fibrosis in older animals were confirmed by gamma counting ( < .05) and histologic evaluation, respectively. Coadministration of a nonradiolabeled probe in excess abolished the elevated radiotracer binding in the aged transgenic hearts. Importantly, PET tracer accumulation was also detected in younger (7 months of age) transgenic mice with intermediate cardiac fibrosis, although this was only apparent from 20 minutes following injection (1.6-2.2-fold binding increase; < .05). Conclusion The T-peptide PET tracer targeting proteolyzed collagen IV provided a sensitive and specific approach of detecting diffuse cardiac fibrosis at varying degrees of severity in a transgenic mouse model. Diffuse Cardiac Fibrosis, Molecular Peptide Probe, Molecular Imaging, PET/CT © RSNA, 2024.
目的 利用靶向蛋白水解型 IV 型胶原的肽示踪剂(T 肽),开发一种用于检测活体间质型心肌纤维化的正电子发射断层扫描(PET)方法。
材料与方法 T 肽与铜螯合剂 MeCOSar(化学名:5-(8-甲基-3,6,10,13,16,19-六氮杂双环[6.6.6]icosan-1-基氨基)-5-氧戊酸)偶联,并与铜 64(Cu)进行放射性标记。在静脉注射过表达β2 肾上腺素能受体的转基因小鼠(雄性,7 月龄,每组 4 只;10 月龄,每组 11 只)后,进行 Cu-T-肽-MeCOSar(0.25mg/kg;18MBq±2.7[标准差])的 PET/CT 扫描,以检测中度(7 月龄)至重度(10 月龄)的心脏纤维化。同时,还进行了放射性示踪剂与过量非标记 T 肽共给药的 PET 扫描,以确认结合特异性。通过检验对静态扫描数据和方差分析检验(单向或双向)对动态扫描数据进行分析。
结果 PET/CT 扫描显示,与健康对照组相比,在整个 45 分钟采集期内,年龄较大的转基因β2 肾上腺素能受体小鼠纤维化心脏的 Cu-T-肽-MeCOSar 结合显著升高(2.24-4.26 倍; <.05)。放射性示踪剂的心脏累积量和弥漫性心脏纤维化的存在分别通过伽马计数( <.05)和组织学评估得到证实。过量给予非放射性探针可消除老年转基因心脏中升高的放射性示踪剂结合。重要的是,在有中度心脏纤维化的年轻(7 月龄)转基因小鼠中也检测到了 PET 示踪剂的积累,但仅在注射后 20 分钟时才明显(结合增加 1.6-2.2 倍; <.05)。
结论 靶向蛋白水解型 IV 型胶原的 T 肽 PET 示踪剂为在转基因小鼠模型中检测不同严重程度的弥漫性心脏纤维化提供了一种敏感和特异的方法。弥漫性心肌纤维化,分子肽探针,分子成像,PET/CT